Opening a new pathway
for people with cardiovascular disease
IsomAb is developing a novel approach to treat cardiovascular disease – starting with chronic stable angina, the largest patient group with coronary artery disease.
In chronic stable angina, narrowed coronary arteries and too few collateral vessels leave parts of the heart under‑supplied with blood, causing predictable chest pain on exertion. Existing drugs mainly relieve symptoms and do not address this lack of collateral circulation.
IsomAb scientists have identified why collateral vessels fail to develop in coronary artery disease and have created ISM‑001, a therapeutic antibody designed to restore the heart’s own ability to build a ‘biological bypass’. ISM‑001 specifically neutralizes VEGF‑A165b, an anti‑angiogenic isoform of VEGF‑A that puts the brakes on new vessel growth in people with cardiovascular disease. By removing this brake, ISM‑001 aims to allow vessels to grow, remodel, and form new arteries, improving perfusion where it is most needed.
For chronic stable angina, ISM-001 is to be used to generate a better blood vessel network so that blood can reach parts of the heart fast enough to allow normal function, relieving pain on exercise and improving quality of life.
